IN
INIS
RADNOSTIX INC
$0.0723
+3.29%
No data for this timeframe.
Vol
SEC Reports3
Exchange OTC·Sector Industrial Instruments For Measurement, Display, and Control·Inc. TX·CIK 0001038277·Prev Close $0.0700
Recent Activity
Jun 4, 2026
SEC
Radnostix Inc. filed a DEFA14A (definitive additional proxy soliciting materials) on June 4, 2026. The filing contains n
DEFA14A — Impact 2/10
May 20, 2026
SEC
Radnostix extended the maturity date of its Series C Convertible Redeemable Preferred Stock by one year to February 28,
8-K — Impact 2/10
May 19, 2026
earnings_calendar
INIS Q1 2026 Earnings Scheduled — 2026-05-19
Apr 30, 2026
SEC
Radnostix Inc. (INIS) filed Amendment No. 1 to its 2025 Form 10-K solely to add previously omitted Part III information
10-K/A — Impact 2/10
Mar 11, 2026
Event
Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 49353,49457, 49477. (c) 3 ml V-vial, NDC 69208-003-35; Order 49454,49406. Rx Only, Manufactured by: International Isotopes Inc., Idaho Falls, ID.
Class II: Presence of Particulate Matter: Due to production issues
Feb 17, 2025
Insider
GROSSO CHRISTOPHER G sold 269,999 shares
Director @ $0.00 ($0.00)
Latest Reports
NEUTRAL
DEFA14A
2/10
Radnostix Inc. filed a DEFA14A (definitive additional proxy soliciting materials) on June 4, 2026. The filing contains n
Jun 4, 2026
NEUTRAL
8-K
2/10
Radnostix extended the maturity date of its Series C Convertible Redeemable Preferred Stock by one year to February 28,
May 20, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 17, 2025 | GROSSO CHRISTOPHER | J | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 17, 2025 | GROSSO CHRISTOPHER G | Director | J | 269,999 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 2.0/10.
NEUTRAL
DEFA14A
2/10
Radnostix Inc. filed a DEFA14A (definitive additional proxy soliciting materials) on June 4, 2026. T
Jun 4, 2026
NEUTRAL
8-K
2/10
Radnostix extended the maturity date of its Series C Convertible Redeemable Preferred Stock by one y
May 20, 2026
NEUTRAL
10-K/A
2/10
Radnostix Inc. (INIS) filed Amendment No. 1 to its 2025 Form 10-K solely to add previously omitted P
Apr 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2015-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
earnings_calendar
INIS Q1 2026 Earnings Scheduled — 2026-05-19
Apr 6, 2026
earnings_calendar
INIS Q4 2025 Earnings Scheduled — 2026-04-06
Mar 11, 2026
FDA
Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 49353,49457, 49477. (c) 3 ml V-vial, NDC 69208-003-35; Order 49454,49406. Rx Only, Manufactured by: International Isotopes Inc., Idaho Falls, ID.
Class II: Presence of Particulate Matter: Due to production issues
Mar 11, 2026
FDA
Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 49353,49457, 49477. (c) 3 ml V-vial, NDC 69208-003-35; Order 49454,49406. Rx Only, Manufactured by: International Isotopes Inc., Idaho Falls, ID.
Class II: Presence of Particulate Matter: Due to production issues
Mar 11, 2026
FDA
Sodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317, 49323, 49325, 49329, 49333, 49339, 49341,49355, 49364, 49380, 49392. (b) 2 ml V-Vial, NDC 69208-003-25; Order 49353,49457, 49477. (c) 3 ml V-vial, NDC 69208-003-35; Order 49454,49406. Rx Only, Manufactured by: International Isotopes Inc., Idaho Falls, ID.
Class II: Presence of Particulate Matter: Due to production issues
Mar 2, 2026
earnings_calendar
INIS Q4 2025 Earnings Scheduled — 2026-03-02